VTGN Vistagen Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1411685 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY230.4%
TTM net income YoY5.3%
TTM EPS YoY29.7%
Revenue 3-yr CAGR43.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2,541.9%
Net margin-2,474.5%
FCF margin—
EBITDA margin-2,533.2%
Returns
ROE-144.9%
ROA-113.0%
ROIC (approx.)-1,250.0%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets36.0%
Debt / equity0.00x
Current ratio2.64x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio3.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $138,000 | $1.48M | $465,000 | $303,000 | $258,000 | $244,000 | -$15,000 | $234,000 |
| R&D expense | $6.55M | $10.91M | $13.06M | $14.22M | $15.91M | $11.68M | $10.21M | $11.30M |
| SG&A expense | $4.52M | $3.92M | $4.12M | $5.63M | $4.40M | $4.37M | $4.27M | $4.05M |
| Operating income | -$10.94M | -$13.35M | -$16.72M | -$19.55M | -$20.05M | -$15.80M | -$14.49M | -$15.12M |
| Pretax income | -$10.74M | -$13.03M | -$16.27M | -$18.90M | -$19.42M | -$15.10M | -$13.63M | -$14.09M |
| Income tax | $0 | $0 | $7,000 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$10.74M | -$13.03M | -$16.27M | -$18.90M | -$19.42M | -$15.10M | -$13.63M | -$14.09M |
| EBITDA | -$10.89M | -$13.30M | -$16.66M | -$19.49M | -$20.00M | -$15.76M | -$14.46M | -$15.08M |
| EPS (basic) | -0.24 | -0.30 | — | -0.45 | -0.54 | -0.47 | — | -0.46 |
| EPS (diluted) | -0.24 | -0.30 | — | -0.45 | -0.54 | -0.47 | — | -0.46 |
| Weighted avg. shares (diluted) | 44.44M | 42.98M | — | 42.23M | 35.75M | 31.93M | — | 30.71M |
| Balance sheet | ||||||||
| Cash & equivalents | $10.89M | $16.99M | $30.79M | $47.37M | $62.79M | $48.98M | $67.13M | $74.72M |
| Short-term investments | $9.14M | $14.74M | $14.61M | $14.40M | $14.39M | $14.20M | $13.35M | $13.85M |
| Current assets | $22.29M | $34.31M | $46.94M | $63.24M | $78.93M | $66.72M | $82.08M | $89.94M |
| PP&E, net | $325,000 | $375,000 | $427,000 | $480,000 | $516,000 | $530,000 | $476,000 | $428,000 |
| Total assets | $23.42M | $35.74M | $48.56M | $65.06M | $80.93M | $68.92M | $84.34M | $92.31M |
| Current liabilities | $8.43M | $11.19M | $12.79M | $13.53M | $13.64M | $11.15M | $12.61M | $9.62M |
| Total liabilities | $8.43M | $11.26M | $13.04M | $14.14M | $14.59M | $12.16M | $13.95M | $11.19M |
| Shareholders' equity | $14.99M | $24.48M | $35.52M | $50.92M | $66.34M | $56.77M | $70.39M | $81.12M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.16M | -$14.71M | -$16.20M | -$17.63M | -$13.76M | -$18.85M | -$10.06M | -$10.28M |
| Investing cash flow | $5.71M | $0 | -$99,000 | $104,000 | -$94,000 | -$788,000 | $527,000 | -$422,000 |
| Financing cash flow | $351,000 | $909,000 | -$283,000 | $2.11M | $27.65M | $1.49M | $1.95M | $1.17M |
| Depreciation & amortization | $50,000 | $52,000 | $52,000 | $54,000 | $53,000 | $40,000 | $40,000 | $39,000 |
| Stock-based compensation | $907,000 | $991,000 | $889,000 | $1.10M | $1.10M | $916,000 | $963,000 | $1.08M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.